|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600119392 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-26 11:42:34 |
|
注册时间: Date of Registration: |
2026-02-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
高危HPV阳性患者生殖道及肠道微生态与子宫颈病变转归关联的纵向研究 |
|
Public title: |
A longitudinal study on the association of reproductive tract and intestinal microecology with recurrence of cervical lesions in high-risk HPV-positive patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
高危HPV阳性患者生殖道及肠道微生态与子宫颈病变转归关联的纵向研究 |
|
Scientific title: |
A longitudinal study on the association of reproductive tract and intestinal microecology with recurrence of cervical lesions in high-risk HPV-positive patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴顶峰 |
研究负责人: |
王薇 |
|
Applicant: |
Dingfeng Wu |
Study leader: |
Wei Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 21 20261381 |
研究负责人电话:
Study leader's |
+86 20 83062650 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wudingfeng@51mch.com |
研究负责人电子邮件: Study leader's E-mail: |
gyfyywangwei@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦东新区高科西路2699号 |
研究负责人通讯地址: |
上海市浦东新区高科西路2699号 |
|
Applicant address: |
2699 Gaokexi Road, Pudong New District, Shanghai |
Study leader's address: |
2699 Gaokexi Road, Pudong New District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第一妇婴保健院 |
||
|
Applicant's institution: |
Shanghai First Maternity Infant Hospital |
||
|
研究负责人所在单位: |
上海市第一妇婴保健院 |
||
|
Affiliation of the Leader: |
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)伦审第(226)号; (2025)伦审第(393)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第一妇婴保健院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee, Shanghai First Maternity and Infant Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-01 00:00:00 | ||
|
伦理委员会联系人: |
李春林 |
||
|
Contact Name of the ethic committee: |
Li Chunlin |
||
|
伦理委员会联系地址: |
上海市浦东新区高科西路2699号 |
||
|
Contact Address of the ethic committee: |
2699 Gaokexi Road, Pudong New District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 20261211 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
clli18@fudan.edu.cn |
|
研究实施负责(组长)单位: |
上海市第一妇婴保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市浦东新区高科西路2699号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2699 Gaokexi Road, Pudong New District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
生殖健康及重大出生缺陷防控研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China |
||||||||||||||||||||||
|
研究疾病: |
HR-HPV阳性女性患者 |
||||||||||||||||||||||
|
Target disease: |
High Risk HPV-positive female |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
(1)描述不同宫颈病变状态下HR-HPV阳性患者的生殖道微生态特征; (2)分析HR-HPV阳性患者生殖道及肠道微生态与子宫颈病变转归的关联并建立AI预测模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Describing the reproductive tract microecological characteristics of HR-HPV-positive patients under different cervical lesion states ; (2) Analyzing the association of reproductive tract and intestinal microbiology with cervical lesion regression in HR-HPV-positive patients and establishing AI prediction models. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄:18-65岁; 2.有性生活史的非妊娠期非哺乳期女性; 3.HR-HPV感染患者 且未行宫颈手术、物理、光动力或药物等治疗; 4.自愿加入本研究,签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age: 18-65 years; 2. Non-pregnancy and non-feeding women with a sexual history; 3. HR-HPV-infected patients who have not undergone cervical surgery, physical, photodynamic or drug-based treatment; 4. Voluntary participation in this study and signing a informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 近3个月抗生素、抗真菌类药物用药史; 2. 近1个周内有性生活、阴道灌洗、局部用药史; 3. 近1个月无便秘腹泻等不适症状; 4. 存在急性生殖道炎症不适合阴道采样者; 5. 既往全子宫切除史、盆腔放射治疗病史; 6. 合并免疫系统疾病、糖尿病、严重肝肾功能不全者; 7. 既往恶性肿瘤病史或结核病史或器官移植病史; 8. HIV确证感染史。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. History of use of antibiotics and antifungal drugs for the past 3 months; 2. History of sexual life, vaginal irrigation, and local drug use for the past 1 week; 3. History of absence of constipation, diarrhea, and other discomfort symptoms for the past 1 month; 4. History of acute genital tract inflammation unsuitable for vaginal sampling; 5. History of total hysterectomy and pelvic radiotherapy; 6. History of combined immune system disease, diabetes, and severe liver and kidney dysfunction; 7. History of malignancy or tuberculosis or organ transplantation; 8. History of confirmed HIV infection. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-13 00:00:00至 To 2028-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-02 00:00:00 至 To 2028-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NONE |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
no |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用院内EDC_plus进行数据收集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection was conducted using the in-hospital EDC_plus system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |